This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Glancy Binkow & Goldberg LLP reminds investors that all purchasers of the securities of
Nu Skin Enterprises, Inc. (“Nu Skin” or the “Company”) (NYSE:NUS) between October 25, 2011 and January 15, 2014, inclusive (the “Class Period”), have until March 24, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
Nu Skin develops and distributes anti-aging personal care products and nutritional supplements worldwide under the Nu Skin and Pharmanex brands. The Complaint alleges that the Company and certain of its executive officers misrepresented or failed to disclose that the Company’s business practices in China operated as an illegal pyramid scheme and did not comply with local laws and regulations, and the Company’s rapid growth and revenue increases could not continue without its China business.
If you purchased Nu Skin securities during the Class Period, you may move the Court no later than March 24, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact
Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact
Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to
firstname.lastname@example.org, or visit our website at
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.